IL-15 Superagonists for Reprogramming the Immunosuppressive Microenvironment in Gastrointestinal Adenocarcinomas

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Gastrointestinal (GI) adenocarcinomas are challenging to treat due to immunosuppressive tumor microenvironments.
• Pancreatic ductal adenocarcinoma (PDAC) and gastric cancer often exhibit immune exclusion and resistance to immune checkpoint inhibitors.
• Current immunotherapies face limitations in effectively engaging the tumor microenvironment.

Purpose of the Study:

• To explore the potential of IL-15 superagonists as a novel immunotherapeutic strategy for GI adenocarcinomas.
• To investigate combination therapies involving IL-15 superagonists to overcome treatment resistance.
• To evaluate localized delivery methods for enhancing therapeutic efficacy and reducing toxicity.

Main Methods:

• Preclinical and early clinical data analysis of IL-15 superagonists (e.g., N-803, NIZ985).
• Investigating combinations with TGF-β/IL-10 inhibitors, stromal remodelling agents, and vascular normalization strategies.
• Exploring localized delivery systems like endoscopic delivery, depots, scaffolds, and nanocarriers.

Main Results:

• IL-15 superagonists selectively expand natural killer (NK) and CD8+ T-cells with reduced toxicity compared to IL-2.
• Combination therapies effectively circumvent immune barriers, improve lymphocyte trafficking, and normalize tumor vasculature.
• Localized delivery enhances intratumoral cytokine retention and minimizes systemic inflammatory side effects.

Conclusions:

• IL-15 superagonists represent a promising cytokine-immunotherapy paradigm for reprogramming the tumor microenvironment in GI cancers.
• These agents can restore cytotoxic immunity and enhance responsiveness to checkpoint blockade.
• Further clinical validation is required to establish IL-15-targeted therapies for immune-cold GI malignancies.